{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:49:20Z","timestamp":1776829760728,"version":"3.51.2"},"reference-count":0,"publisher":"American Society of Hematology","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Peripheral T-cell lymphomas (PTCL) have marked biologic and clinical heterogeneity, which confounds treatment decisions. Advances in circulating tumor DNA (ctDNA) assays employing next generation sequencing (NGS) has improved the detection of molecular relapse and driver mutations in diffuse large B-cell lymphoma, and highlight the potential utility of ctDNA across lymphomas. We investigated NGS-based monitoring of T-cell receptor (TCR) sequences in PTCL patients undergoing frontline treatment (NCT00001337). Of 45 patients, 34 (76%) had tumor-specific clonotypes of the TCR \u03b2 or \u0263 genes identified, which included 18 (86%) from baseline tissue and 16 (67%) from baseline serum. Twenty-five (74%) patients had both TCR\u03b2 and TCR\u0263 clonotypes, 23 (68%) patients had more than one TCR\u0263 clonotype, and 4 (9%) had multiple TCR\u03b2 or TCR\u0263 clonotypes, demonstrating significant intra-patient clonotypic heterogeneity. Among 24 patients with available serial serum samples during treatment, 9 (38%) cleared ctDNA after 2 cycles of therapy, and 11 (46%) patients had detectable ctDNA at the end of treatment. Patients with detectable ctDNA after therapy showed a trend towards worse survival. Notably, two patients with persistently detectable ctDNA after therapy remain in remission with 10-years of follow-up. Clonotypic heterogeneity in tumors and persistence despite long-term remission suggests variability in oncological potential.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003679","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T19:57:28Z","timestamp":1629921448000},"update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Next-Generation Sequencing-Based Monitoring of Circulating Tumor DNA Reveals Clonotypic Heterogeneity in Untreated PTCL"],"prefix":"10.1182","author":[{"given":"Milos D","family":"Miljkovic","sequence":"first","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9661-4570","authenticated-orcid":false,"given":"Christopher","family":"Melani","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-1439","authenticated-orcid":false,"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3123-6844","authenticated-orcid":false,"given":"Rahul","family":"Lakhotia","sequence":"additional","affiliation":[{"name":"National Cancer Institute, Bethesda, Maryland, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Nicole","family":"Lucas","sequence":"additional","affiliation":[{"name":"NCI, Bethesda, Maryland, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison P","family":"Jacob","sequence":"additional","affiliation":[{"name":"Adaptive Biotechnologies, Seattle, Washington, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Yusko","sequence":"additional","affiliation":[{"name":"Adaptive Biotechnologies, Seattle, Washington, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-0301","authenticated-orcid":false,"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"National Cancer Institute Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-2635","authenticated-orcid":false,"given":"Mark J.","family":"Roschewski","sequence":"additional","affiliation":[{"name":"National Cancer Institute, NIH, Bethesda, Maryland, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2021,8,25]]},"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2020003679\/1819574\/bloodadvances.2020003679.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/doi\/10.1182\/bloodadvances.2020003679\/1819574\/bloodadvances.2020003679.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T19:57:30Z","timestamp":1629921450000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/doi\/10.1182\/bloodadvances.2020003679\/476668\/Next-Generation-Sequencing-Based-Monitoring-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003679","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"article-number":"bloodadvances.2020003679"}}